DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count

Executive Summary

• DiagnosTear Technologies Inc. has signed a non‑binding term sheet to exclusively license the “CLARIFY” imaging platform from Sheba Medical Center and Tel Aviv University.
• The CLARIFY technology enables needle‑free blood component analysis via spectral imaging of scleral vasculature, targeting rapid point‑of‑care diagnostics.
• The parties will negotiate a definitive research and licensing agreement that includes a structured clinical development plan and commercialization pathway.

Key Details

• Parties Involved: DiagnosTear Technologies Inc.; Sheba Impact (Technology Transfer Office of Sheba Medical Center); Ramot (Technology Transfer Office of Tel Aviv University).
• Technology Licensed: “CLARIFY” – an imaging platform that performs blood counts and analyzes blood‑related parameters through eye‑surface imaging.
• Developers: Prof. Haim Suchowski (TAU) and Prof. Ygal Rotenstreich (Sheba MC); feasibility demonstrated during an Israeli space mission in microgravity.
• Intended Use Cases: Chronic care monitoring, emergency settings, and other clinical environments requiring rapid, painless diagnostics without traditional blood draws.
• Term Sheet Status: Non‑binding; serves as a framework for a future definitive research and licensing agreement.
• Future Plans: Development of a comprehensive clinical development plan, product evaluation pathways, and eventual commercialization strategy.
• Management Comments:
• Dr. Shimon Gross (CEO) highlighted the collaboration as a major step toward bringing CLARIFY to patients and accelerating clinical evaluation.
• Dr. Avital Beck (Business Development Manager) emphasized the potential of needle‑free, rapid blood monitoring to improve patient comfort and decision‑making.
• Forward‑Looking Statements: The release contains forward‑looking statements regarding the term sheet, potential collaboration, definitive agreement, and technology performance; outcomes may differ materially from expectations.

Notable Quotes

“This potential collaboration represents a major step in bringing CLARIFY closer to patients,” – Dr. Shimon Gross, CEO, DiagnosTear Technologies Inc.

“We believe CLARIFY has the potential to redefine how frequent blood monitoring is performed,” – Dr. Avital Beck, Business Development Manager, DiagnosTear Technologies Inc.